We are live on
!
Find out more
PSC
Patient Square Capital Portfolio holdings
AUM
$564M
1-Year Est. Return
261.3%
This Fund
S&P 500
This Quarter
Est. Return
-9.77%
1 Year Est. Return
+261.3%
3 Year Est. Return
+328.19%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$242M
AUM Growth
-$25.7M
(-9.6%)
Cap. Flow
+$6.93M
Cap. Flow
% of AUM
2.87%
Top 10 Holdings %
Top 10 Hldgs %
89.15%
Holding
24
New
4
Increased
12
Reduced
1
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kymera Therapeutics
KYMR
|
+$5.18M |
| 2 |
Scholar Rock
SRRK
|
+$4.69M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
+$3.76M |
| 4 |
Ocular Therapeutix
OCUL
|
+$3.45M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
+$2.43M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$6.01M |
| 2 |
Liquidia Corp
LQDA
|
+$4.93M |
| 3 |
Geron
GERN
|
+$4.68M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$3.37M |
| 5 |
Arvinas
ARVN
|
+$1.66M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Roivant Sciences
ROIV
$24.1B
| $126M | 52.09% |
12,480,000
| – | – |
|
2
Insmed
INSM
$21.3B
| $25.2M | 10.42% |
330,250
+23,083
| +8% | +$1.77M |
|
|
3
Liquidia Corp
LQDA
$7.46B
| $22.5M | 9.29% |
1,522,452
-337,919
| -18% | -$4.93M |
|
4
EyePoint Inc
EYPT
$1.04B
| $8.03M | 3.32% |
1,481,977
+71,646
| +5% | +$501K |
|
|
5
Ocular Therapeutix
OCUL
$1.84B
| $6.75M | 2.79% |
920,199
+449,280
| +95% | +$3.45M |
|
6
Cullinan Oncology
CGEM
$999M
| $6.65M | 2.75% |
878,897
| – | – |
|
7
Nurix Therapeutics
NRIX
$2.41B
| $5.31M | 2.2% |
447,296
+1,000
| +0.2% | +$16.7K |
|
|
8
Mirum Pharmaceuticals
MIRM
$6.38B
| $5.24M | 2.17% |
116,362
+51,462
| +79% | +$2.43M |
|
9
Enliven Therapeutics
ELVN
$4.15B
| $5M | 2.07% |
253,838
+29,800
| +13% | +$641K |
|
|
10
Scholar Rock
SRRK
$5.49B
| $4.95M | 2.05% |
154,000
+122,000
| +381% | +$4.69M |
|
11
Disc Medicine
IRON
$2.93B
| $4.12M | 1.7% |
83,000
+26,600
| +47% | +$1.48M |
|
12
Agios Pharmaceuticals
AGIO
$1.82B
| $4.09M | 1.69% |
139,732
+18,000
| +15% | +$597K |
|
|
13
Kymera Therapeutics
KYMR
$8.25B
| $3.89M | 1.61% |
+142,201
| New | +$5.18M |
|
14
Pharvaris
PHVS
$2.25B
| $3.85M | 1.59% |
245,496
+37,893
| +18% | +$639K |
|
15
Allogene Therapeutics
ALLO
$635M
| $3.46M | 1.43% |
2,368,186
+878,277
| +59% | +$1.66M |
|
|
BPMC
16
DELISTED
Blueprint Medicines
BPMC
| $3.41M | 1.41% |
+38,500
| New | +$3.76M |
|
17
Intellia Therapeutics
NTLA
$1.5B
| $1.66M | 0.68% |
232,781
+16,800
| +8% | +$170K |
|
|
SLNO
18
DELISTED
Soleno Therapeutics
SLNO
| $1.33M | 0.55% |
+18,600
| New | +$906K |
|
|
YARW
19
Yarrow Bioscience, Inc. Common Stock
YARW
$22.4M
| $406K | 0.17% |
+5,141
| New | +$633K |
|
|
20
Arvinas
ARVN
$520M
| – | – |
-86,627
| Closed | -$1.66M |
|
|
ATXS
21
DELISTED
Astria Therapeutics
ATXS
| – | – |
-105,057
| Closed | -$939K |
|
|
22
Geron
GERN
$821M
| – | – |
-1,321,268
| Closed | -$4.68M |
|
|
SWTX
23
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-93,137
| Closed | -$3.37M |
|
|
ITCI
24
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-71,990
| Closed | -$6.01M |
|
Similar funds
TCP
AHSW
KF
KBG
AAS
LC
AMCA
OC
Patient Square Capital's Q1 2025 Portfolio in Review
As of Q1 2025, Patient Square Capital held 24 positions worth $242M, down 9.6% from $267M the previous quarter. Its ten largest holdings account for 89% of the portfolio.
Patient Square Capital's Q1 2025 filing shows 4 new, 12 increased, 1 reduced and 5 closed positions. Its largest new stake was Kymera Therapeutics: 142,201 shares worth $3.89M. The largest sale was Intra-Cellular Therapies Inc., an estimated $6.01M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Patient Square Capital's largest Q1 2025 buy was Kymera Therapeutics: 142,201 shares worth $3.89M.
- Patient Square Capital added most to Scholar Rock in Q1 2025, an estimated $4.69M increase.
- Patient Square Capital's biggest Q1 2025 reduction was Liquidia Corp, cutting an estimated $4.93M.
- Patient Square Capital fully exited Intra-Cellular Therapies Inc. in Q1 2025, selling an estimated $6.01M.
- Patient Square Capital's ten largest holdings make up 89% of its $242M portfolio in Q1 2025.
- Patient Square Capital opened 4 new positions and closed 5 in Q1 2025.
- Patient Square Capital's portfolio value fell 9.6% quarter-over-quarter to $242M.
Based on Patient Square Capital's 13F filing for Q1 2025, filed 14 May 2025.